Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica
Executive Summary
The delay in FDA approval of Idec's non-Hodgkin's lymphoma treatment Zevalin could also cause a delay in finalizing Medicare reimbursement for the product
You may also be interested in...
Idec Zevalin Targets Up To 40,000 Rituxan-Refractory NHL Patients
Idec's Zevalin is expected to target the 30% of non-Hodgkin's lymphoma patients refractory to Idec/ Genentech's Rituxan (rituximab), Idec President Bill Rohn said
Idec Zevalin Targets Up To 40,000 Rituxan-Refractory NHL Patients
Idec's Zevalin is expected to target the 30% of non-Hodgkin's lymphoma patients refractory to Idec/ Genentech's Rituxan (rituximab), Idec President Bill Rohn said
GSK Tabloid Shortage Due To Catalytica Problems; Emergency Ordering Set Up
GlaxoSmithKline is supplying Tabloid on an emergency basis through pharmacies while the acute nonlymphocytic leukemia product is in short supply